Next Article in Journal
Comparative Assessment of Antioxidant Activity and Functional Components of Chionanthus virginicus and Chionanthus pubescens from the Andean Region of Ecuador
Previous Article in Journal
Pullulan/Poly(vinyl alcohol) Hydrogels Loaded with Calendula officinalis Extract: Design and In Vitro Evaluation for Wound Healing Applications
Previous Article in Special Issue
Development of Triamcinolone Acetonide Nanocrystals for Ocular Administration
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Nanoparticles in Ocular Drug Delivery Systems

by
Hugo Almeida
1,2,3,* and
Ana Catarina Silva
1,2,4,*
1
UCIBIO (Research Unit on Applied Molecular Biosciences), REQUIMTE (Rede de Química e Tecnologia), MEDTECH (Medicines and Healthcare Products), Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
2
Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
3
Mesosystem Investigação & Investimentos by Spinpark, Barco, 4805-017 Guimarães, Portugal
4
FP-BHS (Biomedical and Health Sciences Research Unit), FP-I3ID (Instituto de Investigação, Inovação e Desenvolvimento), Faculty of Health Sciences, University Fernando Pessoa, 4249-004 Porto, Portugal
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2023, 15(6), 1675; https://doi.org/10.3390/pharmaceutics15061675
Submission received: 2 June 2023 / Accepted: 6 June 2023 / Published: 8 June 2023
(This article belongs to the Special Issue Nanoparticles in Ocular Drug Delivery Systems)
Conventional ophthalmic formulations lack a prolonged drug release effect and mucoadhesive properties, decreasing their residence time in the precorneal area and, therefore, in drug penetration across ocular tissues, presenting low bioavailability with a consequent reduction in therapeutic efficacy. These limitations are related to the physiological mechanisms of the eye. To increase the residence time in formulations on the surface of ocular tissues and increase their ability to penetrate these tissues, different strategies can be used, namely, the use of viscosifying agents, mucoadhesive polymers, stimuli-responsive polymers, microparticles, and colloidal carriers (e.g., micelles, liposomes, nanosuspensions, nanoemulsions, and polymeric and lipid nanoparticles).
We are delighted to present the latest research and review works reporting on the use of nanoparticles and other nanosystems in ophthalmic formulations to increase the bioavailability of drugs, improving their therapeutic efficacy. The articles selected for this Special Issue are the following:
  • “Development of Triamcinolone Acetonide Nanocrystals for Ocular Administration” [1].
  • “Design, Characterization and Pharmacokinetic–Pharmacodynamic Evaluation of Poloxamer and Kappa-Carrageenan-Based Dual-Responsive In Situ Gel of Nebivolol for Treatment of Open-Angle Glaucoma” [2].
  • “Cannabidiol Loaded Topical Ophthalmic Nanoemulsion Lowers Intraocular Pressure in Normotensive Dutch-Belted Rabbits” [3].
  • “Enhanced Ocular Anti-Aspergillus Activity of Tolnaftate Employing Novel Cosolvent-Modified Spanlastics: Formulation, Statistical Optimization, Kill Kinetics, Ex Vivo Trans-Corneal Permeation, In Vivo Histopathological and Susceptibility Study” [4].
  • “Photodisruption of the Inner Limiting Membrane: Exploring ICG Loaded Nanoparticles as Photosensitizers” [5].
  • “Linoleic Acid-Based Transferosomes for Topical Ocular Delivery of Cyclosporine A” [6].
  • “Ciprofloxacin-Loaded Zein/Hyaluronic Acid Nanoparticles for Ocular Mucosa Delivery” [7].
  • “Physicochemical and Stability Evaluation of Topical Niosomal Encapsulating Fosinopril/γ-Cyclodextrin Complex for Ocular Delivery” [8].
  • “Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma” [9].
  • “Ocular Delivery of Therapeutic Proteins: A Review” [10].
  • “Bioprinted Membranes for Corneal Tissue Engineering: A Review” [11].
  • “Fluorescent Nanosystems for Drug Tracking and Theranostics: Recent Applications in the Ocular Field” [12].
The selected articles highlight the use of nanotechnology in ophthalmic formulations to encapsulate molecules with different therapeutic applications, including antibiotics, anti-inflammatory drugs, natural compounds, and proteins. The use of nanosystems in different approaches, such as theranostics and nanobubbles, is also presented, showing their potential for ocular application.
We would like to take this opportunity to thank all the authors and reviewers for their incredible work. Without their contribution, it would not be possible to publish this Special Issue with such high scientific quality. We hope that the readers of this Special Issue enjoy these articles, and that they will serve as a starting point for further research and/or review articles, thus contributing to scientific discovery and progress in this field.

Funding

The Applied Molecular Biosciences Unit—UCIBIO—which is financed by national funds from Fundação para a Ciência e a Tecnologia—FCT—(UIDP/04378/2020 and UIDB/04378/2020), supported this work.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Formica, M.L.; Awde Alfonso, H.G.; Paredes, A.J.; Melian, M.E.; Camacho, N.M.; Faccio, R.; Tártara, L.I.; Palma, S.D. Development of Triamcinolone Acetonide Nanocrystals for Ocular Administration. Pharmaceutics 2023, 15, 683. [Google Scholar] [CrossRef] [PubMed]
  2. Rawat, P.S.; Ravi, P.R.; Mir, S.I.; Khan, M.S.; Kathuria, H.; Katnapally, P.; Bhatnagar, U. Design, Characterization and Pharmacokinetic–Pharmacodynamic Evaluation of Poloxamer and Kappa-Carrageenan-Based Dual-Responsive In Situ Gel of Nebivolol for Treatment of Open-Angle Glaucoma. Pharmaceutics 2023, 15, 405. [Google Scholar] [CrossRef] [PubMed]
  3. Senapati, S.; Youssef, A.A.A.; Sweeney, C.; Cai, C.; Dudhipala, N.; Majumdar, S. Cannabidiol Loaded Topical Ophthalmic Nanoemulsion Lowers Intraocular Pressure in Normotensive Dutch-Belted Rabbits. Pharmaceutics 2022, 14, 2585. [Google Scholar] [CrossRef] [PubMed]
  4. Aziz, D.; Mohamed, S.A.; Tayel, S.; Makhlouf, A. Enhanced Ocular Anti-Aspergillus Activity of Tolnaftate Employing Novel Cosolvent-Modified Spanlastics: Formulation, Statistical Optimization, Kill Kinetics, Ex Vivo Trans-Corneal Permeation, In Vivo Histopathological and Susceptibility Study. Pharmaceutics 2022, 14, 1746. [Google Scholar] [CrossRef] [PubMed]
  5. De Clerck, K.; Accou, G.; Sauvage, F.; Braeckmans, K.; De Smedt, S.C.; Remaut, K.; Peynshaert, K. Photodisruption of the Inner Limiting Membrane: Exploring ICG Loaded Nanoparticles as Photosensitizers. Pharmaceutics 2022, 14, 1716. [Google Scholar] [CrossRef] [PubMed]
  6. Uwaezuoke, O.; Du Toit, L.C.; Kumar, P.; Ally, N.; Choonara, Y.E. Linoleic Acid-Based Transferosomes for Topical Ocular Delivery of Cyclosporine A. Pharmaceutics 2022, 14, 1695. [Google Scholar] [CrossRef] [PubMed]
  7. Jacinto, T.A.; Oliveira, B.; Miguel, S.P.; Ribeiro, M.P.; Coutinho, P. Ciprofloxacin-Loaded Zein/Hyaluronic Acid Nanoparticles for Ocular Mucosa Delivery. Pharmaceutics 2022, 14, 1557. [Google Scholar] [CrossRef] [PubMed]
  8. Hnin, H.M.; Stefánsson, E.; Loftsson, T.; Asasutjarit, R.; Charnvanich, D.; Jansook, P. Physicochemical and Stability Evaluation of Topical Niosomal Encapsulating Fosinopril/γ-Cyclodextrin Complex for Ocular Delivery. Pharmaceutics 2022, 14, 1147. [Google Scholar] [CrossRef] [PubMed]
  9. Albarqi, H.A.; Garg, A.; Ahmad, M.Z.; Alqahtani, A.A.; Walbi, I.A.; Ahmad, J. Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma. Pharmaceutics 2023, 15, 681. [Google Scholar] [CrossRef] [PubMed]
  10. Shastri, D.H.; Silva, A.C.; Almeida, H. Ocular Delivery of Therapeutic Proteins: A Review. Pharmaceutics 2023, 15, 205. [Google Scholar] [CrossRef] [PubMed]
  11. Orash Mahmoud Salehi, A.; Heidari-Keshel, S.; Poursamar, S.A.; Zarrabi, A.; Sefat, F.; Mamidi, N.; Behrouz, M.J.; Rafienia, M. Bioprinted Membranes for Corneal Tissue Engineering: A Review. Pharmaceutics 2022, 14, 2797. [Google Scholar] [CrossRef] [PubMed]
  12. Zingale, E.; Romeo, A.; Rizzo, S.; Cimino, C.; Bonaccorso, A.; Carbone, C.; Musumeci, T.; Pignatello, R. Fluorescent Nanosystems for Drug Tracking and Theranostics: Recent Applications in the Ocular Field. Pharmaceutics 2022, 14, 955. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Almeida, H.; Silva, A.C. Nanoparticles in Ocular Drug Delivery Systems. Pharmaceutics 2023, 15, 1675. https://doi.org/10.3390/pharmaceutics15061675

AMA Style

Almeida H, Silva AC. Nanoparticles in Ocular Drug Delivery Systems. Pharmaceutics. 2023; 15(6):1675. https://doi.org/10.3390/pharmaceutics15061675

Chicago/Turabian Style

Almeida, Hugo, and Ana Catarina Silva. 2023. "Nanoparticles in Ocular Drug Delivery Systems" Pharmaceutics 15, no. 6: 1675. https://doi.org/10.3390/pharmaceutics15061675

APA Style

Almeida, H., & Silva, A. C. (2023). Nanoparticles in Ocular Drug Delivery Systems. Pharmaceutics, 15(6), 1675. https://doi.org/10.3390/pharmaceutics15061675

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop